Amphetamine Analogs Increase Plasma Serotonin: Implications for Cardiac and Pulmonary Disease

Clinical Psychopharmacology Section, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA.
Journal of Pharmacology and Experimental Therapeutics (Impact Factor: 3.97). 09/2006; 318(2):604-10. DOI: 10.1124/jpet.106.101618
Source: PubMed


Elevations in plasma serotonin (5-HT) have been implicated in the pathogenesis of cardiac and pulmonary disease. Normally, plasma 5-HT concentrations are kept low by transporter-mediated uptake of 5-HT into platelets and by metabolism to 5-hydroxyindoleacetic acid (5-HIAA). Many abused drugs (e.g., substituted amphetamines) and prescribed medications (e.g., fluoxetine) target 5-HT transporters and could thereby influence circulating 5-HT. We evaluated the effects of amphetamines analogs [(+/-)-fenfluramine, (+/-)-3,4-methylenedioxymethamphetamine, (+)-methamphetamine, (+)-amphetamine, phentermine] on extracellular levels (i.e., plasma levels) of 5-HT and 5-HIAA in blood from catheterized rats. Effects of the 5-HT uptake blocker fluoxetine were examined for comparison. Drugs were tested in vivo and in vitro; plasma indoles were measured using a novel microdialysis method in whole blood. We found that baseline dialysate levels of 5-HT are approximately 0.22 nM, and amphetamine analogs evoke large dose-dependent increases in plasma 5-HT ranging from 4 to 20 nM. The ability of drugs to elevate plasma 5-HT is positively correlated with their potency as 5-HT transporter substrates. Fluoxetine produced small, but significant, increases in plasma 5-HT. Although the drug-evoked 5-HT concentrations are below the micromolar levels required for contraction of pulmonary arteries, they approach concentrations reported to stimulate mitogenesis in pulmonary artery smooth muscle cells. Additional studies are needed to determine the effects of chronic administration of amphetamines on circulating 5-HT.

Download full-text


Available from: Richard B Rothman, Dec 14, 2015
  • Source
    • "Recent studies in rats show that METH also produces significant dose dependent increases in plasma serotonin (Zolkowska et al., 2006; Rothman et al., 2008; Yubera-Lahoz et al., 2012). Because platelets and neurons express the same serotonin transporter (SERT) protein (Lesch et al., 1993) and 99% of the circulating serotonin is stored in platelets (Zolkowska et al., 2006), the elevations in plasma serotonin may well be mediated, at least in part, via interactions of METH with these platelet SERT proteins (Zolkowska et al., 2006; Rothman et al., 2008; Yubera-Lahoz et al., 2012). The association between METH-induced plasma serotonin and body temperature changes was, however, not examined in these studies and remains to be investigated. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Reports of methamphetamine-related emergency room visits suggest that elevated body temperature is a universal presenting symptom, with lethal overdoses generally associated with extreme hyperthermia. This review summarizes the available information on methamphetamine toxicity as it pertains to elevations in body temperature. First, a brief overview of thermoregulatory mechanisms is presented. Next, central and peripheral targets that have been considered for potential involvement in methamphetamine hyperthermia are discussed. Finally, future areas of investigation are proposed, as further studies are needed to provide greater insight into the mechanisms that mediate the alterations in body temperature elicited by methamphetamine.
    Full-text · Article · May 2014 · Pharmacology [?] Therapeutics
  • Source
    • "In summary, antidepressants appear to modulate melatonin via three main mechanisms: pineal β-adrenoceptor stimulation by elevated levels of norepinephrine in the synaptic junction, though this effect seems susceptible to adaptive desensitization of receptors; modulation of melatonin catabolism; serotonergic stimulation of the suprachiasmatic nuclei by projections from the raphe nuclei which modulate the response of the suprachiasmatic nuclei to light signals from the retinohypothalamic tract. Antidepressants also may modulate melatonin by a direct effect on expression of the enzymes involved in its synthesis, and the increase in circulating serotonin by some antidepressants like monoamine oxidase inhibitors and fluoxetine can be another mechanism.166,167 Fewer studies have investigated the effects of selective serotonin reuptake inhibitors on melatonin. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Antidepressant pharmacotherapy is to date the most often used treatment for depression, but the exact mechanism of action underlying its therapeutic effect is still unclear. Many theories have been put forward to account for depression, as well as antidepressant activity, but none of them is exhaustive. Neuroimmune endocrine impairment is found in depressed patients; high levels of circulating corticosteroids along with hyperactivation of the immune system, high levels of proinflammatory cytokines, low levels of melatonin in plasma and urine, and disentrainment of circadian rhythms have been demonstrated. Moreover, antidepressant treatment seems to correct or at least to interfere with these alterations. In this review, we summarize the complex neuroimmune endocrine and chronobiological alterations found in patients with depression and how these systems interact with each other. We also explain how antidepressant therapy can modify these systems, along with some possible mechanisms of action shown in animal and human models.
    Full-text · Article · Feb 2012 · Neuropsychiatric Disease and Treatment
  • Source
    • "In the present study, we assessed the effects of MDMA and its metabolites on plasma 5-HT by administering these drugs directly into whole blood specimens via reverse dialysis. Consistent with previously published data (Zolkowska et al., 2006), we found that MDMA caused potent dose-related increases in plasma 5-HT. It is also shown for the first time that MDA produces marked elevations in plasma 5-HT, whereas HMMA and HMA are less effective. "
    [Show abstract] [Hide abstract]
    ABSTRACT: (±)-3,4-Methylenedioxymethamphetamine (MDMA) is an illicit drug that evokes transporter-mediated release of serotonin (5-HT) in the brain. 5-HT transporter (SERT) proteins are also expressed in non-neural tissues (e.g., blood), and evidence suggests that MDMA targets platelet SERT to increase plasma 5-HT. Here we tested two hypotheses related to the effects of MDMA on circulating 5-HT. First, to determine if MDMA metabolites might contribute to actions of the drug in vivo, we used in vitro microdialysis in rat blood specimens to examine the effects of MDMA and its metabolites on plasma 5-HT. Second, to determine whether effects of MDMA on plasma 5-HT might be used as an index of central SERT activity, we carried out in vivo microdialysis in blood and brain after intravenous MDMA administration. The in vitro results show that test drugs evoke dose-related increases in plasma 5-HT ranging from two- to sevenfold above baseline, with MDMA and its metabolite, (±)-3,4-methylenedioxyamphetamine (MDA), producing the largest effects. The ability of MDMA and related analogs to elevate plasma 5-HT is correlated with their potency as SERT substrates in rat brain synaptosomes. The in vivo results reveal that MDMA causes concurrent increases in extracellular 5-HT in blood and brain, but there are substantial individual differences in responsiveness to the drug. Collectively, our findings indicate that MDMA and its metabolites increase plasma 5-HT by a SERT-dependent mechanism, and suggest the possibility that measures of evoked 5-HT release in blood may reflect central SERT activity.
    Full-text · Article · Nov 2011 · European journal of pharmacology
Show more